Catheter Precision (NYSEAMERICAN:VTAK) Announces Earnings Results

Posted by Joseph Griffin on Aug 16th, 2026

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($19.00) by $18.08, FiscalAI reports. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $2.00 million.

Catheter Precision Stock Down 3.4%

VTAK stock opened at $0.28 on Friday. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.01 million, a PE ratio of -0.04 and a beta of -1.00. Catheter Precision has a 1-year low of $0.23 and a 1-year high of $4.31. The business’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $1.05.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent reporting period. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Company Profile

(Get Free Report)

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.